Wilbanks Smith & Thomas Asset Management LLC raised its position in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,817 shares of the medical equipment provider’s stock after purchasing an additional 550 shares during the period. Wilbanks Smith & Thomas Asset Management LLC’s holdings in Zimmer Biomet were worth $2,753,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of Nova Scotia Trust Co. bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $112,000. FNY Managed Accounts LLC bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $117,000. Cerebellum GP LLC bought a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $133,000. Steward Partners Investment Advisory LLC bought a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $140,000. Finally, Chesley Taft & Associates LLC bought a new position in shares of Zimmer Biomet in the 4th quarter valued at approximately $202,000. 86.36% of the stock is owned by institutional investors.
A number of research analysts recently weighed in on the company. Jefferies Group reissued a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet in a research note on Friday, November 3rd. SunTrust Banks raised their price objective on Zimmer Biomet to $142.00 and gave the company a “buy” rating in a research note on Monday, January 29th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research report on Friday, November 3rd. TheStreet downgraded Zimmer Biomet from a “b-” rating to a “c+” rating in a research report on Friday, November 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zimmer Biomet in a research report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet currently has an average rating of “Buy” and an average price target of $141.67.
Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $116.52 on Tuesday. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The firm has a market capitalization of $23,565.84, a P/E ratio of 12.93, a PEG ratio of 2.04 and a beta of 1.08. The company has a current ratio of 1.52, a quick ratio of 0.83 and a debt-to-equity ratio of 0.76.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same quarter last year, the firm earned $2.14 EPS. Zimmer Biomet’s revenue for the quarter was up 3.0% compared to the same quarter last year. research analysts expect that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s payout ratio is presently 10.65%.
WARNING: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/13/wilbanks-smith-thomas-asset-management-llc-purchases-550-shares-of-zimmer-biomet-holdings-inc-zbh.html.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.